SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (14744)12/17/2004 3:09:41 PM
From: Casaubon  Read Replies (1) | Respond to of 52153
 
nope, no lawyer! I was the last stand out on it being attributed to a class effect. I doubted that aspirin would have shown beneficial due to COX-1 inhibition but, here we are.

As fas as prescribing lower doses, well this is going to need more scrutiny, IMO. I'll be sticking to ibuprofen.

This opens the door of opportunity for a novel mechanism of pain treatment!



To: zeta1961 who wrote (14744)12/17/2004 3:42:45 PM
From: Ian@SI  Read Replies (1) | Respond to of 52153
 
According to Hank McK during CNBC interview, there's a little more than 16,000 deaths annually due to peptic ulcers. I didn't pick up whether or not that was the total USA count or just those caused by NSAIDs.

do you know how many deaths/hospitalizations occur on an annual basis for non-suicidal intended overdoses?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News